Episode

TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions

Podcast: Decera Clinical Education Oncology Podcast
Published: Apr 13, 2026
Duration seconds: 1993
Processing state: not_requested
Canonical source: https://oncologypodcast.simplecast.com/episodes/trop2-directed-antibodydrug-conjugates-in-non-small-cell-lung-cancer-current-use-in-clinical-practice-and-future-directions-c_sZINJs
Audio: https://afp-928689-injected.calisto.simplecastaudio.com/1d8e143b-904e-45be-b6c5-8fba793d9d74/episodes/4a04d9c6-1471-44cc-9b3a-d5aa54f5ce98/audio/128/default.mp3?aid=rss_feed&awCollectionId=1d8e143b-904e-45be-b6c5-8fba793d9d74&awEpisodeId=4a04d9c6-1471-44cc-9b3a-d5aa54f5ce98&feed=GlfUTtJq
JSON: /v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/trop2-directed-antibody-drug-conjugates-in-non-small-cell-lung-cancer-current-use-in-clinical-practice-and-future-directions
Markdown: /podcast/decera-clinical-education-oncology-podcast-1302999/trop2-directed-antibody-drug-conjugates-in-non-small-cell-lung-cancer-current-use-in-clinical-practice-and-future-directions.md

Actions

POST https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/trop2-directed-antibody-drug-conjugates-in-non-small-cell-lung-cancer-current-use-in-clinical-practice-and-future-directions/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/trop2-directed-antibody-drug-conjugates-in-non-small-cell-lung-cancer-current-use-in-clinical-practice-and-future-directions.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode, experts discuss the available efficacy and safety evidence along with their experiences with and strategies for integrating TROP2-directed antibody-drug conjugates into the management of patients with advanced NSCLC, with an emphasis on EGFR-mutant disease and a look at future therapeutic directions on the horizon.